AU2023330441A1 - Il2 variant and protein complex comprising same - Google Patents

Il2 variant and protein complex comprising same Download PDF

Info

Publication number
AU2023330441A1
AU2023330441A1 AU2023330441A AU2023330441A AU2023330441A1 AU 2023330441 A1 AU2023330441 A1 AU 2023330441A1 AU 2023330441 A AU2023330441 A AU 2023330441A AU 2023330441 A AU2023330441 A AU 2023330441A AU 2023330441 A1 AU2023330441 A1 AU 2023330441A1
Authority
AU
Australia
Prior art keywords
protein
variant
antibody
protein complex
constant region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023330441A
Other languages
English (en)
Inventor
Hyo Joo Bang
Sun Jung Cho
Sung Youb Jung
Yong Jun Jung
Seok Chan Kang
Bom Park
Sang Hyun Park
Young Jin Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mustbio Co Ltd
Original Assignee
Mustbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mustbio Co Ltd filed Critical Mustbio Co Ltd
Publication of AU2023330441A1 publication Critical patent/AU2023330441A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2023330441A 2022-08-23 2023-08-21 Il2 variant and protein complex comprising same Pending AU2023330441A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20220105643 2022-08-23
KR10-2022-0105643 2022-08-23
KR20230057361 2023-05-02
KR10-2023-0057361 2023-05-02
PCT/KR2023/012348 WO2024043643A1 (ko) 2022-08-23 2023-08-21 Il2 변이체 및 이를 포함하는 단백질 복합체

Publications (1)

Publication Number Publication Date
AU2023330441A1 true AU2023330441A1 (en) 2025-02-20

Family

ID=90013668

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023330441A Pending AU2023330441A1 (en) 2022-08-23 2023-08-21 Il2 variant and protein complex comprising same

Country Status (6)

Country Link
EP (1) EP4578871A1 (https=)
JP (1) JP2025527694A (https=)
KR (1) KR102655850B1 (https=)
CN (1) CN119790064A (https=)
AU (1) AU2023330441A1 (https=)
WO (1) WO2024043643A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
AU2013258834B2 (en) * 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
DK3186283T3 (da) * 2014-08-29 2020-03-02 Hoffmann La Roche Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
AU2017213659B2 (en) * 2016-02-05 2024-04-18 Washington University Compositions and methods for targeted cytokine delivery
AU2017335771A1 (en) * 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
EP3504234A4 (en) * 2016-09-29 2020-12-02 Beijing Hanmi Pharmaceutical Co., Ltd. CONSTRUCTIONS OF HETERODIMERIC IMMUNOGLOBULINS AND THEIR PREPARATION PROCESSES
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
MY201482A (en) * 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
IL275426B2 (en) * 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
JP2022554141A (ja) 2019-10-25 2022-12-28 オーデンツ セラピューティクス，インコーポレーテッド 糖原病を治療するための組成物及び方法
KR102559355B1 (ko) * 2020-01-31 2023-07-25 주식회사 제넥신 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
CN118271419A (zh) * 2020-03-31 2024-07-02 韩美药品株式会社 新型免疫刺激il-2类似物
US20240034854A1 (en) 2020-08-26 2024-02-01 Reventas Limited Improvements In Or Relating To Plastic Recycling

Also Published As

Publication number Publication date
JP2025527694A (ja) 2025-08-22
KR20240028310A (ko) 2024-03-05
WO2024043643A1 (ko) 2024-02-29
EP4578871A1 (en) 2025-07-02
CN119790064A (zh) 2025-04-08
KR102655850B1 (ko) 2024-04-11

Similar Documents

Publication Publication Date Title
US20230051701A1 (en) Antibodies against cd73 and uses thereof
AU2024201912A1 (en) Antibodies specific to human poliovirus receptor (PVR)
US12331119B2 (en) Modified Fc fragment, antibody comprising same, and application thereof
US10053517B2 (en) Hybrid constant regions
AU2019261411B2 (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
JP6125489B2 (ja) 抗ｃｄ４０抗体および使用方法
US9540442B2 (en) Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
JP2025020138A (ja) 免疫細胞活性化のための二重特異性抗体
AU2023283519A1 (en) Multi-specific antibody targeting bcma, gprc5d and t cells and application thereof
CA3115285A1 (en) Pd-1 single domain antibodies and therapeutic compositions thereof
JP2016532692A (ja) ホモ多量体化ペプチドにより多量体化した抗体または融合タンパク質
AU2023285832A1 (en) Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
TW200823237A (en) Antibodies to NTB-A
CN104334722A (zh) 具有修饰的cdr的抗-涎免凝集素15抗体
JP2022538375A (ja) Ｐｄ－１と結合する抗体
AU2023247712A1 (en) Anti-TIGIT-anti-PVRIG bispecific antibody, pharmaceutical composition thereof and use thereof
AU2023295644A1 (en) Bispecific antibody containing anti-cldn18.2 antibody, and pharmaceutical composition and use thereof
AU2022389530A1 (en) Bispecific antibody against tigit and pd-l1, and pharmaceutical composition thereof and use thereof
AU2023404602A1 (en) Cldn18.2/4-1bb binding protein and medical use thereof
AU2023300868A1 (en) Isolated antigen-binding protein and use thereof
AU2023370296A1 (en) Anti-cd16a antibody and application thereof
AU2023217152A1 (en) Immunoconjugate and use thereof
AU2023330441A1 (en) Il2 variant and protein complex comprising same
EP4722254A1 (en) Anti-fgfr2/pd-1 bispecific antibody
AU2023271380A1 (en) Bispecific humanized single domain antibody to pd-l1 and cd47, and use thereof